FAQ - Our COVID-19 Vaccine Candidates

1. How are you contributing to the fight against COVID-19?

We have executed an extensive development program which was based on innovative and proven manufacturing technology to create our protein-based adjuvanted COVID-19 booster vaccine.

Our COVID-19 vaccine was developed in partnership with GSK and BARDA and is approved in Europe.

We are continuing to study our vaccine against emerging variants and in additional populations. We will also collect data and real-world evidence to help us understand how our vaccine performs in clinical settings.

Finally, we are leveraging our Industrial Affairs capacities worldwide to manufacture authorized COVID-19 vaccines.

2. Where is your vaccine made?

We have activated our manufacturing footprint across our sites in Europe and in the US and to support our COVID-19 manufacturing.

3. When will it be available to countries?

Our vaccine is approved in Europe and will be available in Europe in the next few weeks. You can find information on availability from Local Health Authorities.

4. What are the future plans for your vaccine? Do you plan to develop an Omicron adapted vaccine?

As the regulatory and epidemiological environment continues to evolve, we remain committed to working closely with regulatory authorities to understand the future need for vaccines and how to respond to them appropriately.

5. Can people receive your COVID-19 vaccine and the flu vaccine at the same time?

Many public health authorities and the World Health Organization (WHO) have advised that licensed COVID-19 vaccines (or boosters) and licensed flu vaccines can be given at the same time to help reduce the number of healthcare visits and provide timely protection against both diseases.

6. Does Sanofi have an mRNA COVID-19 vaccine candidate?

On September 28, 2021, we reported positive phase 1/2 study interim results for our mRNA COVID-19 vaccine candidate. Taking into account public health needs and given sufficient mRNA COVID-19 vaccines supply can be expected going forward, we decided not to pursue the development of that COVID-19 mRNA candidate into a Phase 3 clinical study.

The initial data confirmed the potential of Sanofi’s mRNA and Lipid nanoparticle (LNP) platform. We are now focusing our mRNA resources in our newly created mRNA Center of Excellence to address future pandemics and other infectious diseases and therapeutics where there is a strong unmet need.